Page last updated: 2024-11-10

hymecromone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hymecromone: A coumarin derivative possessing properties as a spasmolytic, choleretic and light-protective agent. It is also used in ANALYTICAL CHEMISTRY TECHNIQUES for the determination of NITRIC ACID. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5280567
CHEMBL ID12208
CHEBI ID17224
SCHEMBL ID24150
MeSH IDM0010801

Synonyms (183)

Synonym
MLS001074671
smr000471886
BRD-K46424862-001-02-6
BRD-K46424862-001-04-2
himecromona
7-hydroxy-4-methyl-2h-1-benzopyran-2-one
7-hydroxy-4-methyl-2-oxo-3-chromene
4-mu
beta-methylumbelliferone
7-hydroxy-4-methyl-2h-chromen-2-one
CHEBI:17224 ,
7-hydroxy-4-methyl-2-oxo-2h-1-benzopyran
hymecromonum
ZZ1 ,
NCI60_042099
D00170
hymecromone (jp17/usan/inn)
cantabiline (tn)
bilicante
2h-1-benzopyren-2-one, 7-hydroxy-4-methyl-
nsc 9408
2h-1-benzopyran, 7-hydroxy-4-methyl-2-oxo-
coumarin, 7-hydroxy-4-methyl-
cantabiline
coumarin 4
lm 94
methylumbelliferone, beta
omega 127
mendiaxon
cholonerton
bilcolic
cholestil
hymecromon
2h-1-benzopyran-2-one, 7-hydroxy-4-methyl-
eurogale
cumarote-c
lm-94
.beta.-methylumbelliferone
wln: t66 bovj e1 iq
4-methylumbelliferon
nsc 19026
cantabilin
crodimon
7-hydroxy-4-methylcoumarin
nsc9408 ,
medilla
imecromone
4-methyl-7-hydroxycoumarin
nsc-9408
nsc-19026
nsc19026 ,
pilot 447
NCGC00016345-01
cas-90-33-5
BSPBIO_000742
7-hydroxy-4-methyl-2h-2-chromenone
4-methyl-umbelliferone
7-hydroxy-4-methyl-chromen-2-one
PRESTWICK3_000901
PRESTWICK2_000901
ACON1_002401
AB00443536
ai3-08085
einecs 201-986-7
hymecromonum [inn-latin]
himecromona [inn-spanish]
4-methylumbelliferon [czech]
imecromone [dcit]
ccris 5926
brn 0142217
resocyanine
STK364326
90-33-5
C03081
4-methylumbelliferone ,
hymecromone
SR-01000637483-1
MAYBRIDGE1_002078
PRESTWICK1_000901
PRESTWICK0_000901
SPBIO_002941
BPBIO1_000818
MEGXP0_001898
NCGC00169880-01
NCGC00169880-02
7-hydroxy-4-methyl-coumarin
4 methylumbelliferone
M-5410
4-methylumbelliferone, >=98%
DB07118
HMS547G10
CHEMBL12208 ,
FT-0660634
FT-0658701
M0453
HMS1570F04
coumarin derivative, 3b
cid_5280567
bdbm50022178
AKOS000119370
A843515
BBL000531
HMS2097F04
HMS3264E04
7-hydroxy-4-methylchromen-2-one
NCGC00257522-01
tox21_300915
nsc-760397
pharmakon1600-01506174
hymechrome
nsc760397
dtxsid8025670 ,
dtxcid805670
tox21_110385
F1918-0038
4-METHYLUMBELLIFERONE - 4-MU
HMS2267L19
CCG-47894
NCGC00016345-05
NCGC00016345-03
NCGC00016345-04
NCGC00016345-02
79566-13-5
7h-1-benzopyran-7-one, 2-hydroxy-4-methyl-
hymecromone [usan:inn:ban:jan]
5-18-01-00439 (beilstein handbook reference)
unii-3t5ng4q468
3t5ng4q468 ,
FT-0602257
NCGC00016345-09
MLS004491718
4mu ,
S2256
SCHEMBL24150
tox21_110385_1
NCGC00016345-08
hymecromone [usan]
hymecromone [mart.]
hymecromone [ep monograph]
hymecromone [inn]
hymecromone [jan]
hymecromone [mi]
hymecromone [who-dd]
a-methylumbelliferone
7-hydroxy-4-methyl coumarin
4-methyl umbelliferone
7-hydroxy-4-methyl coumarine
4-methyl-7-hydroxy-coumarin
7-hydroxy-4-methyl-2h-chromen-2-one #
himecol
methylumbelliferone, .beta.
cholspasmin
umbelliferone, 4-methyl-
biliton h
AM85958
2h-1-benzopyran-2-one,7-hydroxy-4-methyl-
4-methylumbelliferone (4-mu)
CS-7560
AC-22306
AB00443536_08
mfcd00006866
4-methyl-7-hydroxyl coumarin
F0849-0318
SR-01000637483-3
sr-01000637483
HMS3655L16
1569304-40-0
HMS3714F04
SW197287-3
HY-N0187
BCP06770
7-hydroxy-4-methyl-coumari
2-hydroxy-4-methyl-7h-chromen-7-one
hymecromohe,(s)
AS-13247
Q904431
EN300-16753
D70647
7-hydroxy-4-methyl-2-coumarin
4-methyl-7-hydroxy-cumarin
7-hydroxy-4-methylcoumarin|4-methylumbelliferone
SY017941
Z56763041

Research Excerpts

Overview

Hymecromone is an important coumarin drug, and carprofen is one of the most important nonsteroidal antiinflammatory drugs (NSAIDs) It is a nontoxic dietary supplement with some antitumor activity at high doses.

ExcerptReferenceRelevance
"Hymecromone is an important coumarin drug, and carprofen is one of the most important nonsteroidal antiinflammatory drugs (NSAIDs). "( Albumin's Influence on Carprofen Enantiomers-Hymecromone Interaction.
Dang, X; Gao, Y; Guo, Y; Sun, Y; Tang, C; Tang, M; Wang, K; Zhou, Z, 2016
)
2.14
"Hymecromone is a nontoxic dietary supplement with some antitumor activity at high doses of 450 to 3,000 mg per day."( Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
Benitez, A; Bowen, T; Lokeshwar, VB; Shamaldevi, N; Yates, TJ, 2013
)
1.44

Toxicity

ExcerptReferenceRelevance
"We describe a new method that uses a fluorogenic bioassay of the beta-glucuronidase conversion of 4-methylumbelliferyl beta-D-glucuronide (MUG) to 4-methylumbelliferone to evaluate the individual toxic effects on Escherichia coli of Al3+, Cr6+, Hg2+ and Li+."( New toxicity determination method that uses fluorescent assay of Escherichia coli.
Carnero, M; Fernández-Crehuet, J; García, A; Gómez, E; Mariscal, A, 1994
)
0.29
" A single toxic dose of CCl(4) (1."( Protective effects of coumarin and coumarin derivatives against carbon tetrachloride-induced acute hepatotoxicity in rats.
Atmaca, M; Deniz Obay, B; Ketani, A; Murat Bilgin, H; Ozekinci, S; Taşdemir, E, 2011
)
0.37
" No serious adverse effect was observed during this experiment."( The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice.
Higaki, K; Li, L; Luan, Z; Nanba, E; Ohno, K; Suzuki, Y, 2013
)
0.39
" However, the percentage of dead hemocytes increased and hematopoiesis significantly decreased in HOs, indicating the toxic effect of 4-MU on hemocytes and hematopoiesis, despite it inducing enhanced antioxidant and antimicrobial activity in the circulatory system."( Hematopoiesis toxicity induced by 4-methylumbelliferon determined in an invertebrate model organism.
Fang, Y; He, Y; Sima, Y; Wang, H; Xing, R; Xu, S; Yan, S; Yin, W, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic behavior of 4-methylumbelliferone (4-MU), a compound known to be excreted as conjugated metabolites, was studied in mice and the results were compared with those reported in rats."( Pharmacokinetic study of 4-methylumbelliferone in mice.
Hanano, M; Iga, T; Sawada, Y; Sugiyama, Y; Suzuki, H, 1987
)
0.27
" The half-life of the major rate constant averaged 28 +/- 2 min (SE)."( Pharmacokinetics and bioavailabilities of hymecromone in human volunteers.
Cerda, JJ; Eberst, K; Garrett, ER; Venitz, J, 1993
)
0.55
" Subsequently, in silico pharmacokinetic (PK) and physiology-based pharmacokinetic (PBPK) modeling was used to determine UGT1A9 maturation and hepatic clearance."( Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics.
Collier, AC; Coughtrie, MW; Milne, AM; Miyagi, SJ, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" The aim of the present study was to develop an in vitro assay for assessment of drug-drug interactions related to UGTs applicable to early drug discovery."( Development of an assay using 4-trifluoromethylumbelliferyl as a marker substrate for assessment of drug-drug interactions to multiple isoforms of UDP-glucuronosyltransferases.
Aberg, M; Andersson, A; Baranczewski, P; Hagigi, S; Kallin, A; Mankowitz, L; Postlind, H, 2004
)
0.32
"We aimed to investigate and compare the effects of erlotinib and gefitinib on UDP-glucuronosyltransferase (UGT) activities and to quantitatively evaluate their drug-drug interaction (DDI) potential due to UGT inhibition."( Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
House, L; Liu, Y; Ramírez, J; Ratain, MJ, 2010
)
0.36
" Based on the concentration of MPA in human liver, the magnitude of in vivo drug-drug interaction (DDI) was predicted."( Strong inhibitory effect of medroxyprogesterone acetate (MPA) on UDP-glucuronosyltransferase (UGT) 2B7 might induce drug-drug interactions.
Fang, ZZ; Huang, T; Yang, L, 2010
)
0.36
" Inhibitory activity of compounds towards UDP-glucuronosyltransferase (UGT) is an important cause of clinical drug-drug interactions and herb-drug interactions."( Strong inhibition of celastrol towards UDP-glucuronosyl transferase (UGT) 1A6 and 2B7 indicating potential risk of UGT-based herb-drug interaction.
Deng, JP; Gao, XC; Li, G; Ma, RM; Tu, YY; Wang, L; Wang, Q; Yuan, J; Zhang, YS, 2012
)
0.38
" The aim of this research was to survey the effects of dabrafenib on human UDP-glucuronosyltransferases (UGTs) and to evaluate the risk of drug-drug interactions (DDIs)."( Inhibition of human UDP-glucuronosyltransferase enzyme by Dabrafenib: Implications for drug-drug interactions.
Cao, J; Fan, X; Jia, Y; Jiang, L; Liu, Y; Lv, X; Wang, X; Wang, Z; Yan, M; Yin, H, 2021
)
0.62

Bioavailability

4MU is an active compound of approved choleretic drug hymecromone with low bioavailability and a broad spectrum of action. The oral bioavailability estimated from the relative areas under the hymECromone plasma concentration-time curves following oral and i.i. treatment.

ExcerptReferenceRelevance
" Therefore, the anticancer effects of 4-MU, an orally bioavailable and relatively nontoxic agent, are primarily mediated by inhibition of HA signaling."( Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells.
Altman, N; Chi, A; Dhir, N; Escudero, DO; Lokeshwar, SD; Lokeshwar, VB; Lopez, LE; Munoz, D; Shirodkar, SP, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" 4MU is an active compound of approved choleretic drug hymecromone with low bioavailability and a broad spectrum of action."( Inhibition of hyaluronan secretion by novel coumarin compounds and chitin synthesis inhibitors.
Andreichenko, IN; Bulgakova, EV; Dashenkova, NO; Ivankov, DN; Khilya, VP; Kotelevtsev, Y; Krasylov, IV; Maltsev, DI; Mikaelyan, A; Moskvina, VS; Nesterchuk, M; Shashkovskaya, V; Tsitrina, AA, 2021
)
0.87
" In this study, we developed a pipeline to selective add complex-sugars to the aglycone 4-methylumbelliferone (4MU) to help their bioavailability and tumour cell intake."( Glycosylated 4-methylumbelliferone as a targeted therapy for hepatocellular carcinoma.
Breccia, JD; Malvicini, M; Mazzolini, G; Molejon, MI; Sukowati, CHC; Tiribelli, C; Weiz, G, 2022
)
0.72

Dosage Studied

We conducted an open-label, single-center, dose-response study of hymecromone in healthy adults. One group (61 patients) was treated with hymECromone (300 mg tablets at a dosage of 1,200 mg/day, 2 tablets midday and evening) and another group (62 patients) were treated with placebo.

ExcerptRelevanceReference
" Dose-response curves were prepared."( Effect of aryl 4-guanidinobenzoates on the acrosin activity of human spermatozoa.
Jeyendran, RS; Kaminski, JM; Kennedy, W; Reid, DS; Smith, D; Zaneveld, LJ, 1987
)
0.27
" Drugs with flow-limited elimination or mainly oxidative phase I biotransformation should be administered with reduced dosage level while monitoring the serum concentration levels."( [The liver and aging. The effect of age on liver function and drug metabolism].
Femfert, U; Kuntz, HD; May, B, 1987
)
0.27
" Linear dose-response curves were obtained and gave ED50 values (50% inhibition of fertilization) of 230 microM for BD, 27 microM for ABD, 35 nM for MUGB, and 13 nM for NPGB."( Inhibition of in-vitro fertilization of mouse gametes by proteinase inhibitors.
Beyler, SA; Zaneveld, LJ, 1982
)
0.26
" One group (61 patients) was treated with hymecromone (300 mg tablets at a dosage of 1,200 mg/day, 2 tablets midday and evening) and another group (62 patients) was treated with placebo."( Hymecromone in the treatment of motor disorders of the bile ducts: a multicenter, double-blind, placebo-controlled clinical study.
Abate, A; Alimonti, P; Costa, PL; Del Piano, M; Dimartino, V; Lombardo, C; Santini, A; Spina, P, 2001
)
2.02
"The role of Mrp2, Bcrp, and P-glycoprotein in the biliary excretion of acetaminophen sulfate (AS) and glucuronide (AG), 4-methylumbelliferyl sulfate (4MUS) and glucuronide (4MUG), and harmol sulfate (HS) and glucuronide (HG) was studied in Abcc2(-/-), Abcg2(-/-), and Abcb1a(-/-)/Abcb1b(-/-) mouse livers perfused with the respective parent compounds using a cassette dosing approach."( The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice.
Brouwer, KL; Kalvass, JC; Nezasa, K; Patel, NJ; Raub, TJ; Tian, X; Zamek-Gliszczynski, MJ, 2006
)
0.33
" In the present study, the involvement in this process of Mrp3 and Mrp4, two basolateral efflux transporters, was evaluated by analyzing the hepatic basolateral excretion of the glucuronide and sulfate metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3(-/-) and Abcc4(-/-) mice using a cassette dosing approach."( Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice.
Belinsky, MG; Bridges, AS; Brouwer, KL; Kruh, GD; Lee, K; Nezasa, K; Tian, X; Zamek-Gliszczynski, MJ, 2006
)
0.33
" After bolus dosing of preformed 4MUG in the perfusion reservoir of the filtering IPK, the perfusate concentration declined with the terminal half-life of approximately 260 min."( Differential disposition of intra-renal generated and preformed glucuronides: studies with 4-methylumbelliferone and 4-methylumbelliferyl glucuronide in the filtering and nonfiltering isolated perfused rat kidney.
Evans, AM; Knights, KM; Miners, JO; Wang, J, 2011
)
0.37
"A 5-fluorouracil (5-FU) concentration and 4-methylumbelliferone (MU) dosage was analyzed by high-performance liquid chromatography (HPLC)."( 4-Methylumbelliferone Decreases the Hyaluronan-rich Extracellular Matrix and Increases the Effectiveness of 5-Fluorouracil.
Endo, M; Hakamada, K; Kakizaki, I; Kudo, D; Nagase, H; Shimoda, H; Suto, A; Suto, S; Yoshida, E, 2018
)
0.48
"METHODSWe conducted an open-label, single-center, dose-response study of hymecromone in healthy adults."( Oral hymecromone decreases hyaluronan in human study participants.
Arbach, O; Bollyky, JB; Bollyky, PL; Burgener, EB; Demirdjian, S; Dunn, CE; Frymoyer, AR; Goel, R; Kaber, G; Kalinowski, A; Milla, CE; Nagy, N; Pacheco-Navarro, AE; Rajadas, J; Rosser, JI; Saxena, J; Wang, Z, 2022
)
1.47
" Further adjustment on the dosage will be required to benefit functional recovery after SCI."( Low oral dose of 4-methylumbelliferone reduces glial scar but is insufficient to induce functional recovery after spinal cord injury.
Chudíčková, M; Jendelová, P; Kubinová, Š; Kwok, JCF; Martinez-Varea, N; Šimková, Z; Štepánková, K; Urdzíková, LM, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
hyaluronic acid synthesis inhibitorAny compound that inhibits one or more steps in the pathway leading to the synthesis of hyaluronic acid.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydroxycoumarinAny coumarin carrying at least one hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (68)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency6.25590.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency6.25590.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency19.95260.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency11.22025.623417.292931.6228AID485281
acetylcholinesteraseHomo sapiens (human)Potency47.76190.002541.796015,848.9004AID1347398
thioredoxin reductaseRattus norvegicus (Norway rat)Potency54.19560.100020.879379.4328AID588453; AID588456
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency47.59673.189029.884159.4836AID1224846; AID1224894
SMAD family member 2Homo sapiens (human)Potency48.96620.173734.304761.8120AID1347035
GALC proteinHomo sapiens (human)Potency28.183828.183828.183828.1838AID1159614
SMAD family member 3Homo sapiens (human)Potency48.96620.173734.304761.8120AID1347035
TDP1 proteinHomo sapiens (human)Potency20.59620.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency24.89630.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency20.04440.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743040
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency15.84890.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency23.53910.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency48.87990.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency48.55770.000417.946075.1148AID1346795
EWS/FLI fusion proteinHomo sapiens (human)Potency22.20800.001310.157742.8575AID1259252; AID1259253
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency31.06050.000214.376460.0339AID720691; AID720719
retinoid X nuclear receptor alphaHomo sapiens (human)Potency27.65310.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency14.52030.001530.607315,848.9004AID1224848; AID1224849
farnesoid X nuclear receptorHomo sapiens (human)Potency38.14660.375827.485161.6524AID743220; AID743239
estrogen nuclear receptor alphaHomo sapiens (human)Potency34.72630.000229.305416,493.5996AID743069; AID743075; AID743079
GVesicular stomatitis virusPotency17.37680.01238.964839.8107AID1645842
glucocerebrosidaseHomo sapiens (human)Potency14.12540.01268.156944.6684AID2101
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency35.14330.001024.504861.6448AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency39.57390.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency27.19310.023723.228263.5986AID743222; AID743223; AID743241
alpha-galactosidaseHomo sapiens (human)Potency24.06824.466818.391635.4813AID1467; AID2107
activating transcription factor 6Homo sapiens (human)Potency35.29480.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency24.541219.739145.978464.9432AID1159509
Histone H2A.xCricetulus griseus (Chinese hamster)Potency64.41930.039147.5451146.8240AID1224845
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency25.11890.036619.637650.1187AID2112
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency12.58930.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency2.51190.006026.168889.1251AID540317
heat shock protein beta-1Homo sapiens (human)Potency38.22130.042027.378961.6448AID743210; AID743228
importin subunit beta-1 isoform 1Homo sapiens (human)Potency70.79465.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency70.79465.804836.130665.1308AID540263
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency51.91670.000627.21521,122.0200AID743202; AID743219
gemininHomo sapiens (human)Potency17.77600.004611.374133.4983AID624296; AID624297
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency11.22020.251215.843239.8107AID504327
caspase-1 isoform alpha precursorHomo sapiens (human)Potency12.58930.000311.448431.6228AID900
lamin isoform A-delta10Homo sapiens (human)Potency0.00450.891312.067628.1838AID1487
Interferon betaHomo sapiens (human)Potency17.37680.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency17.37680.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency42.88290.002319.595674.0614AID651631; AID720552
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID883
Caspase-7Homo sapiens (human)Potency12.58933.981118.585631.6228AID889
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency17.37680.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency17.37680.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseElectrophorus electricus (electric eel)IC50 (µMol)133.50000.00000.94539.9400AID1378862; AID754043
Carbonic anhydrase 12Homo sapiens (human)Ki43.53000.00021.10439.9000AID1803437; AID641826
Carbonic anhydrase 1Homo sapiens (human)Ki61.91000.00001.372610.0000AID1803437; AID641823
Carbonic anhydrase 2Homo sapiens (human)Ki61.91000.00000.72369.9200AID1803437; AID641824
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)62.00000.00041.877310.0000AID34797
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)24.50000.00101.191310.0000AID516862
Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)IC50 (µMol)200.00000.00011.97318.0000AID539405
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)IC50 (µMol)100.00000.30003.25807.3000AID1222388; AID1222389
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)80.41000.00001.89149.5700AID409943
Testosterone 17-beta-dehydrogenase 3Homo sapiens (human)IC50 (µMol)1.00000.00261.76469.3000AID452459
Small conductance calcium-activated potassium channel protein 3Rattus norvegicus (Norway rat)IC50 (µMol)500.00000.00151.68587.0000AID754042
CholinesteraseEquus caballus (horse)IC50 (µMol)250.05000.00002.22149.4000AID1378863; AID754042
Sorbitol dehydrogenaseHomo sapiens (human)IC50 (µMol)153.00000.24000.49531.0000AID516864
Induced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)IC50 (µMol)103.70000.00442.923510.0000AID1701173
Induced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)Ki22.15000.00101.46539.5400AID1701173
Carbonic anhydrase 9Homo sapiens (human)Ki42.02200.00010.78749.9000AID1803437; AID641825
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (297)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to lipopolysaccharideNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
JNK cascadeNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of gene expressionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of lipid storageNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of calcidiol 1-monooxygenase activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of vitamin D biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of cholesterol transportNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of interleukin-12 productionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to muscle stretchNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
B cell receptor signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of protein metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mammary gland involutionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription initiation by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to mechanical stimulusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to nicotineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-1Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-6Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to tumor necrosis factorNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to dsRNANuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-17Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to virusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
antibacterial innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of hyaluronan biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to angiotensinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of miRNA metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
acute-phase responseUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to nutrientUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
animal organ regenerationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to lipopolysaccharideUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to starvationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
negative regulation of steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
biphenyl catabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to ethanolUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to glucocorticoid stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to estradiol stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
androgen biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
male genitalia developmentTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
steroid biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
glucose metabolic processSorbitol dehydrogenaseHomo sapiens (human)
sorbitol catabolic processSorbitol dehydrogenaseHomo sapiens (human)
glucuronate catabolic process to xylulose 5-phosphateSorbitol dehydrogenaseHomo sapiens (human)
flagellated sperm motilitySorbitol dehydrogenaseHomo sapiens (human)
fructose biosynthetic processSorbitol dehydrogenaseHomo sapiens (human)
L-xylitol catabolic processSorbitol dehydrogenaseHomo sapiens (human)
L-xylitol metabolic processSorbitol dehydrogenaseHomo sapiens (human)
DNA damage responseInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
response to cytokineInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cell fate determinationInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of autophagyInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cellular homeostasisInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
positive regulation of apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein transmembrane transportInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of anoikisInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial fusionInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
release of cytochrome c from mitochondriaInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (97)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
transcription cis-regulatory region bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription coregulator activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
identical protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
actinin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme inhibitor activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
17-beta-hydroxysteroid dehydrogenase (NADP+) activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
(R,R)-butanediol dehydrogenase activitySorbitol dehydrogenaseHomo sapiens (human)
L-iditol 2-dehydrogenase activitySorbitol dehydrogenaseHomo sapiens (human)
zinc ion bindingSorbitol dehydrogenaseHomo sapiens (human)
carbohydrate bindingSorbitol dehydrogenaseHomo sapiens (human)
identical protein bindingSorbitol dehydrogenaseHomo sapiens (human)
D-xylulose reductase activitySorbitol dehydrogenaseHomo sapiens (human)
D-sorbitol dehydrogenase (acceptor) activitySorbitol dehydrogenaseHomo sapiens (human)
ribitol 2-dehydrogenase activitySorbitol dehydrogenaseHomo sapiens (human)
NAD bindingSorbitol dehydrogenaseHomo sapiens (human)
protein bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein transmembrane transporter activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein heterodimerization activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
BH3 domain bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
channel activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
BH domain bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (57)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular regionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mitochondrionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytosolNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
secretory granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
specific granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription regulator complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
I-kappaB/NF-kappaB complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
NF-kappaB p50/p65 complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
plasma membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
perinuclear region of cytoplasmUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum chaperone complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cytochrome complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
endoplasmic reticulumTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
endoplasmic reticulum membraneTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
intracellular membrane-bounded organelleTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
endoplasmic reticulumTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
extracellular spaceSorbitol dehydrogenaseHomo sapiens (human)
cytosolSorbitol dehydrogenaseHomo sapiens (human)
membraneSorbitol dehydrogenaseHomo sapiens (human)
motile ciliumSorbitol dehydrogenaseHomo sapiens (human)
mitochondrial membraneSorbitol dehydrogenaseHomo sapiens (human)
extracellular exosomeSorbitol dehydrogenaseHomo sapiens (human)
nucleusInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
nucleoplasmInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cytoplasmInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrionInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial outer membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cytosolInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
Bcl-2 family protein complexInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial outer membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (189)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1701173Displacement of FAM-Bid peptide from recombinant N-terminal His6x-tagged human Mcl-1 expressed in Escherichia coli BL21 (DE3) incubated for 30 mins by fluorescence polarization assay2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Synthesis and structure-activity relationship of coumarins as potent Mcl-1 inhibitors for cancer treatment.
AID503241Activity of Streptomyces antibioticus wild-type OleD assessed as as rate of glucoside formation at 10 mM using varying NDP sugar UDP-glucose concentration by enzyme kinetics assay2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503254Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar UDP-6-azido-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID641826Inhibition of human recombinant CA12 after 6 hrs by stopped flow CO2 hydration assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID613470Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced IL-6 production at 10 uM by ELISA2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anti-inflammatory effects of a series of novel 7-hydroxycoumarin derivatives.
AID315168Induction of apoptosis in human U937 cells at 250 uM after 24 hrs2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Structural insights into hydroxycoumarin-induced apoptosis in U-937 cells.
AID1222388Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID503267Activity of Streptomyces antibioticus OleD P67T mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-6-azido-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID317243Inhibition of CK2 in rat liver2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure-activity relationships.
AID568491Antifungal activity against Saccharomyces cerevisiae ATCC 9763 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID516862Inhibition human recombinant aldose reductase 1 by spectrophotometric analysis2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
AID568490Antifungal activity against Candida albicans ATCC 76615 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID503268Activity of Streptomyces antibioticus OleD S132F mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID613472Inhibition of LPS-stimulated COX2 protein expression in mouse J774 cells at 10 uM by chemiluminescence assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anti-inflammatory effects of a series of novel 7-hydroxycoumarin derivatives.
AID599334Antibacterial against Staphylococcus aureus ATCC 6538 at 20 mg/mL after 24 hrs by NCCLS M7-A6 method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and pharmacological activity of O-aminoalkyl derivatives of 7-hydroxycoumarin.
AID503264Activity of Streptomyces antibioticus OleD P67T mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID568482Antimicrobial activity against Staphylococcus aureus ATCC 25923 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID599337Antibacterial against Escherichia coli ATCC 10536 at 20 mg/mL after 24 hrs by NCCLS M7-A6 method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and pharmacological activity of O-aminoalkyl derivatives of 7-hydroxycoumarin.
AID624610Specific activity of expressed human recombinant UGT1A72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID568488Antimicrobial activity against Salmonella typhi ATCC 9484 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID503255Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-4-deoxy-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503260Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-3-amino-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID315165Growth inhibition of human U937 cells by [3H]thymidine incorporation assay2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Structural insights into hydroxycoumarin-induced apoptosis in U-937 cells.
AID754042Inhibition of equine serum BChE using S-butyrylthiocholine iodide as substrate preincubated for 6 mins prior to substrate addition measured at 60 to 180 seconds by Ellman's method2013European journal of medicinal chemistry, Jun, Volume: 64Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID715800Inhibition of clonogenic activity in human U937 cells assessed as reduction of colony formation in soft agar at 100 to 250 uM after 24 hrs using crystal violet staining2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID715783Induction of cell differentiation in human U937 cells assessed as increase of CD11b and CD14 expression at 500 uM after 72 hrs by FACS flow cytometer analysis2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID599332Antibacterial against Bacillus subtilis ATCC 6633 at 20 mg/mL after 24 hrs by NCCLS M7-A6 method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and pharmacological activity of O-aminoalkyl derivatives of 7-hydroxycoumarin.
AID1459793Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM in absence of UDPGA incubated for 5 mins by LC-ESI/MS/MS analysis relative to control2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors.
AID503247Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as rate of glucoside formation at 10 mM using varying NDP sugar UDP-glucose concentration by enzyme kinetics assay2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503272Activity of Streptomyces antibioticus OleD A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID715802Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID409943Inhibition of human recombinant MAOB by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID641825Inhibition of human recombinant CA9 after 6 hrs by stopped flow CO2 hydration assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors.
AID503239Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503262Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-2-amino-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID452459Inhibition of human 17beta-HSD3 expressed in HeLa cells2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.
AID503250Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar UDP-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503261Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-3-amino-6-deoxy-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503265Activity of Streptomyces antibioticus OleD P67T mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-6-deoxy-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503274Activity of Streptomyces antibioticus OleD A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-xylose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID599335Antibacterial against Staphylococcus aureus ATCC 6538P at 20 mg/mL after 24 hrs by NCCLS M7-A6 method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and pharmacological activity of O-aminoalkyl derivatives of 7-hydroxycoumarin.
AID1466810Induction of melanin synthesis in mouse B16 cells assessed as increase in melanin content at 50 uM after 48 hrs measured by spectrophotometric method relative to control2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Synthesis and in vitro biological evaluation of novel coumarin derivatives containing isoxazole moieties on melanin synthesis in B16 cells and inhibition on bacteria.
AID1232358Metabolic stability in mouse liver microsomes assessed as compound remaining incubated for 60 mins in presence of UDPGA (Rvb = 100%)2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID503238Activity of Streptomyces antibioticus OleD A242V mutant assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503249Activity of Streptomyces antibioticus wild-type OleD assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-6-thio-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID641823Inhibition of human full-length cytosolic CA1 after 6 hrs by stopped flow CO2 hydration assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors.
AID25853Photostability, pKa was evaluated1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Synthesis of novel fluorinated coumarins: excellent UV-light excitable fluorescent dyes.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID630751Antioxidant activity assessed as DPPH free radical scavenging activity after 10 mins by UV-Vis spectrophotometric analysis2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Effect of different C3-aryl substituents on the antioxidant activity of 4-hydroxycoumarin derivatives.
AID754041Selectivity index, ratio of IC50 for equine serum BChE to IC50 for electric eel AChE2013European journal of medicinal chemistry, Jun, Volume: 64Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.
AID409944Selectivity ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID568492Antifungal activity against Aspergillus fumigatus ATCC 96918 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID568484Antimicrobial activity against Bacillus subtilis ATCC 6633 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID1328524Gastroprotective activity in Swiss albino mouse assessed as reduction in HCl/EtOH-induced gastric lesions at 20 mg/kg, po pretreated for 50 mins followed by HCl/EtOH challenge measured after 1 hr2016Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23
Gastroprotective activity of synthetic coumarins: Role of endogenous prostaglandins, nitric oxide, non-protein sulfhydryls and vanilloid receptors.
AID503253Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-6-thio-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503251Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar UDP-xylose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID715795Induction of apoptosis in human U937 cells assessed as reduction of normal cells at 500 uM after 24 hrs by Annexin V-FITC double staining2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID568489Antimicrobial activity against Shigella dysenteriae ATCC 49550 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID539405Inhibition of NF-KB p50 subunit/DNA interaction after 20 mins by EMSA2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Virtual screening against nuclear factor κB (NF-κB) of a focus library: Identification of bioactive furocoumarin derivatives inhibiting NF-κB dependent biological functions involved in cystic fibrosis.
AID613464Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced NO production at 10 uM by Griess reaction2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anti-inflammatory effects of a series of novel 7-hydroxycoumarin derivatives.
AID503259Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor-UDP-3-deoxy-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID599330Antibacterial against Micrococcus luteus ATCC 9341 at 20 mg/mL after 24 hrs by NCCLS M7-A6 method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and pharmacological activity of O-aminoalkyl derivatives of 7-hydroxycoumarin.
AID613471Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced IL-6 production at 100 uM by ELISA2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anti-inflammatory effects of a series of novel 7-hydroxycoumarin derivatives.
AID541338Inhibition of alpha-glucosidase using para-nitrophenyl substrate2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
Hydroxycoumarin derivatives: novel and potent α-glucosidase inhibitors.
AID624617Specific activity of expressed human recombinant UGT2B172000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID503246Activity of Streptomyces antibioticus wild-type OleD assessed as conversion rate of compound to produce glucoside 3 using NDP sugar UDP-6-deoxy-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID315167Effect on DNA fragmentation in human U937 cells assessed as ladder-like pattern at 2 mM after 24 hrs2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Structural insights into hydroxycoumarin-induced apoptosis in U-937 cells.
AID503244Ratio of Kcat to Km for Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as as rate of glucoside formation using varying compound concentration by enzyme kinetics assay2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID503258Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-4-amino-6-deoxy-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID613473Inhibition of LPS-stimulated COX2 protein expression in mouse J774 cells at 100 uM by chemiluminescence assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anti-inflammatory effects of a series of novel 7-hydroxycoumarin derivatives.
AID503243Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as as rate of glucoside formation using varying compound concentration by enzyme kinetics assay2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID503273Activity of Streptomyces antibioticus OleD A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-6-deoxy-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503256Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-4-amino-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID613467Inhibition of LPS-stimulated iNOS protein expression in mouse J774 cells at 100 uM by RT-PCR analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anti-inflammatory effects of a series of novel 7-hydroxycoumarin derivatives.
AID503235Activity at Streptomyces antibioticus wild-type OleD assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID630752Antioxidant activity assessed as trolox equivalents of ABTS radical scavenging activity by TEAC assay2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Effect of different C3-aryl substituents on the antioxidant activity of 4-hydroxycoumarin derivatives.
AID315164Cytotoxicity against human U937 cells by trypan blue assay after 48 hrs2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Structural insights into hydroxycoumarin-induced apoptosis in U-937 cells.
AID503269Activity of Streptomyces antibioticus OleD S132F mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-6-deoxy-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID1170033Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents.
AID516865Selectivity index, ratio of IC50 for sorbitol dehydrogenase to IC50 for kidney aldose reductase 22010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
AID1170040Antiproliferative activity against human T29 cells after 48 hrs by MTT assay2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents.
AID568485Antimicrobial activity against Micrococcus luteus ATCC 4698 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID1138893Antiasthamic activity in Wistar rat tracheal ring assessed as reversal of carbachol-induced contraction at 0.1 to 500 uM relative to control2014European journal of medicinal chemistry, Apr-22, Volume: 77Semisynthesis, ex vivo evaluation, and SAR studies of coumarin derivatives as potential antiasthmatic drugs.
AID503257Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor-UDP-4,6-dideoxyglucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503271Activity of Streptomyces antibioticus OleD S132F mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-6-azido-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID715771Pro-oxidant activity in human U937 cells assessed as DCF-DA oxidation at 10 to 250 uM after 48 hrs by fluorescence assay2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID503266Activity of Streptomyces antibioticus OleD P67T mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-xylose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID516863Inhibition kidney aldose reductase 2 by spectrophotometric analysis2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
AID613465Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced NO production at 100 uM by Griess reaction2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anti-inflammatory effects of a series of novel 7-hydroxycoumarin derivatives.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID599325Antibacterial against Bacillus cereus ATCC 11778 after 24 hrs by NCCLS M7-A6 method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and pharmacological activity of O-aminoalkyl derivatives of 7-hydroxycoumarin.
AID409945Inhibition of human recombinant MAOA at 100 uM by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1466811Antifungal activity against Candida albicans ATCC 10231 assessed as diameter of inhibition zone after 24 hrs by agar well diffusion method2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Synthesis and in vitro biological evaluation of novel coumarin derivatives containing isoxazole moieties on melanin synthesis in B16 cells and inhibition on bacteria.
AID599331Antibacterial against Micrococcus luteus ATCC 10240 at 20 mg/mL after 24 hrs by NCCLS M7-A6 method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and pharmacological activity of O-aminoalkyl derivatives of 7-hydroxycoumarin.
AID1222389Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in estradiol 3-glucuronidation by LC-MS/MS method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID503344Activity of Streptomyces antibioticus OleD A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-6-azido-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID715793Induction of apoptosis in human U937 cells assessed as activation of caspase-3 at 500 uM after 24 hrs by colorimetric assay2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID568487Antimicrobial activity against Proteus vulgaris ATCC 6896 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID630753Antioxidant activity in soybean lipoxygenase-induced beta-carotene-linoleic acid co-oxidation assessed as inhibition of beta-carotene bleaching after 10 mins relative to control2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Effect of different C3-aryl substituents on the antioxidant activity of 4-hydroxycoumarin derivatives.
AID1138894Antiasthamic activity in Wistar rat tracheal ring assessed as reversal of carbachol-induced contraction2014European journal of medicinal chemistry, Apr-22, Volume: 77Semisynthesis, ex vivo evaluation, and SAR studies of coumarin derivatives as potential antiasthmatic drugs.
AID1378862Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 6 mins followed by substrate addition measured up to 180 secs by Ellman's method2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID568483Antimicrobial activity against methicillin-resistant Staphylococcus aureus N 315 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID613474Cytotoxicity against mouse J774 cells at 100 uM by XTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anti-inflammatory effects of a series of novel 7-hydroxycoumarin derivatives.
AID568486Antimicrobial activity against Escherichia coli ATCC 25922 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID503237Activity of Streptomyces antibioticus OleD S123F mutant assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503242Ratio of Kcat to Km for Streptomyces antibioticus wild-type OleD assessed as as rate of glucoside formation at 10 mM using varying NDP sugar UDP-glucose concentration by enzyme kinetics assay2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503270Activity of Streptomyces antibioticus OleD S132F mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar donor UDP-xylose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID613466Inhibition of LPS-stimulated iNOS protein expression in mouse J774 cells at 10 uM by RT-PCR analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anti-inflammatory effects of a series of novel 7-hydroxycoumarin derivatives.
AID503263Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar UDP-glucose0 after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503248Ratio of Kcat to Km for Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as rate of glucoside formation at 10 mM using varying NDP sugar UDP-glucose concentration by enzyme kinetics assay2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID503240Ratio of Kcat to Km for Streptomyces antibioticus wild-type OleD assessed as as rate of glucoside formation using varying compound concentration by enzyme kinetics assay2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID1466812Antibacterial activity against Escherichia coli ATCC 11229 assessed as diameter of inhibition zone after 24 hrs by agar well diffusion method2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Synthesis and in vitro biological evaluation of novel coumarin derivatives containing isoxazole moieties on melanin synthesis in B16 cells and inhibition on bacteria.
AID516866Selectivity index, ratio of IC50 for human recombinant aldose reductase 1 to IC50 for kidney aldose reductase 22010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
AID503245Activity of Streptomyces antibioticus wild-type OleD assessed as conversion rate of compound to produce glucoside 3 using NDP sugar UDP-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID624614Specific activity of expressed human recombinant UGT2A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID34797Compound was tested for inhibitory concentration against rat lens aldose reductase (noncompetitive inhibition type)1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis and rat lens aldose reductase inhibitory activity of some benzopyran-2-ones.
AID754034Inhibition of self-induced amyloid beta (1 to 42) (unknown origin) aggregation at 20 uM after 46 to 48 hrs by thioflavin T-based fluorometric assay2013European journal of medicinal chemistry, Jun, Volume: 64Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.
AID516864Inhibition sorbitol dehydrogenase by spectrophotometric analysis2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
AID1378863Inhibition of equine serum BuChE using S-butyrylthiocholine iodide as substrate preincubated for 6 mins followed by substrate addition measured up to 180 secs by Ellman's method2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID715803Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID754043Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 6 mins prior to substrate addition measured at 60 to 180 seconds by Ellman's method2013European journal of medicinal chemistry, Jun, Volume: 64Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.
AID503252Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as conversion rate of compound to produce glucoside 3 using NDP sugar UDP-6-deoxy-glucose after 3 hrs by HPLC2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID599336Antibacterial against Escherichia coli ATCC 8739 at 20 mg/mL after 24 hrs by NCCLS M7-A6 method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and pharmacological activity of O-aminoalkyl derivatives of 7-hydroxycoumarin.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID641824Inhibition of human full-length cytosolic CA2 after 6 hrs by stopped flow CO2 hydration assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors.
AID1466813Antibacterial activity against Staphylococcus aureus ATCC 6538 assessed as diameter of inhibition zone after 24 hrs by agar well diffusion method2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Synthesis and in vitro biological evaluation of novel coumarin derivatives containing isoxazole moieties on melanin synthesis in B16 cells and inhibition on bacteria.
AID1459792Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM preincubated for 5 mins followed by UDPGA addition measured after 30 mins by LC-ESI/MS/MS analysis relative to control2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors.
AID503236Activity of Streptomyces antibioticus OleD P67T mutant assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1803437CA Inhibition Assay from Article 10.3109/14756366.2013.777334: \\Novel coumarins and benzocoumarins acting as isoform-selective inhibitors against the tumor-associated carbonic anhydrase IX.\\2014Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 29, Issue:2
Novel coumarins and benzocoumarins acting as isoform-selective inhibitors against the tumor-associated carbonic anhydrase IX.
AID1799899NS5B Inhibition Assay from Article 10.1111/cbdd.12105: \\Evaluation of Coumarin and Neoflavone Derivatives as HCV NS5B Polymerase Inhibitors.\\2013Chemical biology & drug design, May, Volume: 81, Issue:5
Evaluation of coumarin and neoflavone derivatives as HCV NS5B polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,204)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990391 (32.48)18.7374
1990's235 (19.52)18.2507
2000's219 (18.19)29.6817
2010's288 (23.92)24.3611
2020's71 (5.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.17 (24.57)
Research Supply Index7.14 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index59.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (1.45%)5.53%
Reviews8 (0.64%)6.00%
Case Studies13 (1.05%)4.05%
Observational0 (0.00%)0.25%
Other1,202 (96.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]